A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

Clinical trial NCT02875548 · COMPLETED

Trial details

NCT number: NCT02875548
Sponsor: Epizyme, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Synovial Sarcoma Epitheliod Sarcoma (ES)Mesothelioma Advanced Solid Tumors Renal Medullary Carcinoma Non-Hodgkin Lymphoma (NHL)

Start date: 2016-08-30
Primary completion: 2025-09-26
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.